Outpace Bio
Seattle
About Outpace Bio
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $199.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Aug 2024)
- Website: outpacebio.com
Industries & Categories
Biotechnology, Health Care, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/outpace-bio-30908 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.